Wall Street Zen Upgrades Rallybio (NASDAQ:RLYB) to “Hold”

Rallybio (NASDAQ:RLYB) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Rallybio currently has a consensus rating of “Reduce”.

Rallybio Stock Performance

Shares of Rallybio stock opened at $8.22 on Friday. The company has a 50-day simple moving average of $6.97 and a two-hundred day simple moving average of $5.78. The stock has a market capitalization of $43.48 million, a PE ratio of -3.21 and a beta of -1.13. Rallybio has a 52-week low of $1.76 and a 52-week high of $11.49.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, equities research analysts forecast that Rallybio will post -1.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the period. Citadel Advisors LLC grew its position in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the period. Geode Capital Management LLC raised its stake in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Susquehanna International Group LLP raised its stake in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares during the period. 90.34% of the stock is owned by hedge funds and other institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.